Contact Person: Joanne T. Fuji, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4184, MSC 7850, Bethesda, MD 20892, (301) 435–1178, fuji@csr.nih.gov.

Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group; Cellular and Molecular Biology of Neurodegeneration Study Section.

Date: February 11–12, 2010.
Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.
Place: Palomar Hotel, 2121 P Street, NW., Washington, DC 20037.

Contact Person: Laurent Taupenot, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4138, MSC 7850, Bethesda, MD 20892, 301–435–1203, taupenot@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: SAT and BTSS Study Sections.

Date: February 11, 2010.
Time: 1 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Roberto J. Matus, MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5108, MSC 7854, Bethesda, MD 20892, (301) 435–2204, mutus@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Molecular Probes.

Date: February 12, 2010.
Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.
Place: Gaylord National Hotel & Convention Center, 201 Waterfront Street, National Harbor, MD 20745.

Contact Person: Mary Custer, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7850, Bethesda, MD 20892–7850, (301) 435–1164, custerm@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cognition and Movement.

Date: February 15–16, 2010.
Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Edwin C. Clayton, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5180, MSC 7844, Bethesda, MD 20892, 301–408–9041, clayton@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Addiction and Toxicity.

Date: February 16–17, 2010.
Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Edwin C. Clayton, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5180, MSC 7844, Bethesda, MD 20892, 301–408–9041, clayton@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: SAT and BTSS Study Sections.

Date: February 16, 2010.
Time: 2 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: John Firrell, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5213, MSC 7854, Bethesda, MD 20892, 301–435–2598, firrej@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict SEP: Molecular and Neurogenetics.

Date: February 17, 2010.
Time: 11 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Aidan Hampson, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5199, MSC 7850, Bethesda, MD 20892, (301) 435–0634, hampsona@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Molecular and Developmental Neuroscience Integrated Review Group; Biophysics of Neural Systems Study Section.

Date: February 19, 2010.
Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.
Place: Westin St. Francis Hotel, 335 Powell Street. San Francisco, CA 94102.

Contact Person: Geoffrey G. Schofield, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4040–A, MSC 7850, Bethesda, MD 20892, 301–435–1235, schofield@csr.nih.gov.


Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010–987 Filed 1–19–10; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health
National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, In vivo Cellular and Molecular Imaging Centers (ICMICs).

Date: March 8–9, 2010.
Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.
Place: Washington DC North Hilton Hotel, 620 Perry Parkway, Gaithersburg, MD 20877.

Contact Person: Kenneth L. Bielat, PhD, Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 7147, Bethesda, MD 20892–8329, 301–496–7576, bielatk@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, Developing Research Capacity in Africa for the Studies on HIV-Associated Malignancies.

Date: March 15, 2010.
Time: 7:45 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.
Place: Hilton Alexandria Old Town, 1767 King Street, Alexandria, VA 22314.

Contact Person: Ilda M Mckenna, Scientific Review Officer, Research Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard Room 8111, Bethesda, MD 20892, 301–496–7481, mckennai@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

NIH State-of-the-Science Conference: Preventing Alzheimer’s Disease and Cognitive Decline; Notice

Notice is hereby given by the National Institutes of Health (NIH) of the “NIH State-of-the-Science Conference: Preventing Alzheimer’s Disease and Cognitive Decline” to be held April 26–28, 2010, in the NIH Natcher Conference Center, 45 Center Drive, Bethesda, Maryland 20892. The conference will begin at 8:30 a.m. on April 26 and 27 and at 9 a.m. on April 28, and it will be open to the public.

For many older adults, cognitive health and performance remain stable over the course of their lifetime, with only a gradual and slight decline in short-term memory and reaction times. But for others, this normal, age-related decline in cognitive function progresses into a more serious state of cognitive impairment or into various forms of dementia, including Alzheimer’s disease. Such loss of cognitive function—the ability to think, learn, remember, and reason—substantially interferes with everyday function. As researchers continue to explore changes in the brain that take place possibly decades before cognitive decline and dementia symptoms appear, they also hope to discover more about the relationship between normal age-related cognitive decline and the development of cognitive impairment or Alzheimer’s disease.

Alzheimer’s disease was first described in 1906, when German psychiatrist and neuropathologist Alois Alzheimer observed the hallmarks of the disease in the brain of a female patient who had experienced memory loss, language problems, and unpredictable behavior: abnormal clumps of protein (now called beta-amyloid plaques) and tangled bundles of protein fibers (now called neurofibrillary tangles). Today, an estimated 2.5 to 4.5 million Americans are living with Alzheimer’s, the most common form of dementia, and those numbers are expected to grow with the aging of the baby boomer population. Age is the strongest known risk factor for Alzheimer’s, with most people diagnosed with the late-onset form of the disease over age 60. An early-onset, familial form also occurs, but is very rare. The time from diagnosis to death with Alzheimer’s ranges from as little as 3 years to 10 or more, depending on the person’s age, sex, and the presence of other health problems.

In addition to investigating the causes and potential treatments for Alzheimer’s and other dementias, researchers are focused on finding ways to prevent cognitive decline. Many preventive measures for cognitive decline and for preventing Alzheimer’s—mental stimulation, exercise, and a variety of dietary supplements—have been suggested, but their value in delaying the onset and/or reducing the severity of decline or disease is unclear. Questions also remain as to how the presence of certain conditions, such as high cholesterol, high blood pressure, and diabetes, influence an individual’s risk of cognitive decline and Alzheimer’s disease.

To examine these important questions about Alzheimer’s and cognitive decline in older people, the National Institute on Aging and the Office of Medical Applications of Research of the NIH will convene a State-of-the-Science Conference from April 26 to 28, 2010, to assess the available scientific evidence related to the following questions:

- What factors are associated with the reduction of risk of Alzheimer’s disease?
- What factors are associated with the reduction of risk of cognitive decline in older adults?
- What are the relationships between the factors that affect Alzheimer’s disease and the factors that affect cognitive decline?
- What are the therapeutic and adverse effects of interventions to delay the onset of Alzheimer’s disease?
- What are the therapeutic and adverse effects of interventions to improve or maintain cognitive ability or preserve cognitive function? Are there different outcomes in identifiable subgroups?
- If recommendations for interventions cannot be made currently,